Citation Impact
Citing Papers
Nonclassic Functions of Human Topoisomerase I: Genome-Wide and Pharmacologic Analyses
2007
C-terminal region of activation-induced cytidine deaminase (AID) is required for efficient class switch recombination and gene conversion
2014 StandoutNobel
The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts
2003
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma
2005 StandoutNobel
EGFR Antagonists in Cancer Treatment
2008 Standout
Bioluminescent imaging of Cdk2 inhibition in vivo
2004 StandoutNobel
Angiogenesis: from plants to blood vessels
2006 Standout
A view on drug resistance in cancer
2019 StandoutNature
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1?)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells
2004
Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth
2010
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
2001 Standout
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
Liposomes for the sustained drug release in vivo
1990
The biology of VEGF and its receptors
2003 Standout
Bisindenoisoquinoline Bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity
2006
Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells
2002 StandoutNobel
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Preparation of Large Monodisperse Vesicles
2009 StandoutNobel
The core of hepatitis C virus pathogenesis
2016
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
2009
‘Accidental’ anti-angiogenic drugs
2000
Bioorganometallic chemistry—from teaching paradigms to medicinal applications
2008 Standout
Endothelial cell effects of cytotoxics: balance between desired and unwanted effects
2004
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
2007
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Neuroblastoma
2007 Standout
Tumour-inhibiting platinum complexes—state of the art and future perspectives
2003
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
2016 StandoutNobel
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
2000
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer
2002
Sequence- and Region-Specificity of Oxaliplatin Adducts in Naked and Cellular DNA
1998
Exacerbation of experimental murine cutaneous leishmaniasis with CD4+Leishmania major‐specific T cell lines or clones which secrete interferon‐γ and mediate parasite‐specific delayed‐type hypersensitivity
1991 StandoutNobel
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae
2001
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
Angiogenesis as a therapeutic target
2005 StandoutNature
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Tumor Angiogenesis
2008 Standout
Repair of and checkpoint response to topoisomerase I-mediated DNA damage
2003
Leishmaniasis
1999 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
The Proapoptotic Gene SIVA Is a Direct Transcriptional Target for the Tumor Suppressors p53 and E2F1
2004
Repair of Topoisomerase I‐Mediated DNA Damage
2006
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biologically active quinoline and quinazoline alkaloids part I
2017
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
DNA Topoisomerase I Is a Cofactor for c-Jun in the Regulation of Epidermal Growth Factor Receptor Expression and Cancer Cell Proliferation
2005
Meeting Report: Exploiting the Tumor Microenvironment for Therapeutics
2006 StandoutNobel
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Redefining the Target: Chemotherapeutics as Antiangiogenics
2001
Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts
2004
Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia
2007 StandoutNobel
Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation
2011 StandoutNobel
Homologation of the Fischer Indolization: A Quinoline Synthesis via Homo‐Diaza‐Cope Rearrangement
2020 StandoutNobel
Adaptive and Maladaptive Cardiorespiratory Responses to Continuous and Intermittent Hypoxia Mediated by Hypoxia-Inducible Factors 1 and 2
2012 StandoutNobel
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination
2009 StandoutNobel
Hypoxic induction of an HIF-1α–dependent bFGF autocrine loop drives angiogenesis in human endothelial cells
2005
An Evolutionary View of the Mechanism for Immune and Genome Diversity
2012 StandoutNobel
Advances in leishmaniasis
2005 Standout
Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
2002
Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice
1999
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Leishmaniases of the New World: current concepts and implications for future research
1993
Evolutionary Comparison of the Mechanism of DNA Cleavage with Respect to Immune Diversity and Genomic Instability
2012 StandoutNobel
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8+ T-cell responses in vivo
2000 StandoutNobel
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
1999
APE1 is dispensable for S-region cleavage but required for its repair in class switch recombination
2014 StandoutNobel
Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8+ T-cell responses in vivo
2000 StandoutNobel
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
2004
Works of Sayed S. Daoud being referenced
Characterization of chronic HCV infection-induced apoptosis
2011
Polymerase chain reaction analysis of cisplatininduced mitchondrial DNA damage in human ovarian carcinoma cells
1995
Antiangiogenic potential of camptothecin and topotecan
1999
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G 2 arrest
2000
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells
1997
Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts
1995
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells
2005
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
2003 Nobel
Liposomes in cancer therapy
1989
Variants with reduced virulence derived from Leishmania major after mutagen treatment
1987